Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 252Gynecologic 10Tumor-Agnostic 3Thoracic 2Other 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Sexual Dysfunction, Physiological 1Seizures 1Multiple Endocrine Neoplasia Type 1 1Hypogonadism 1Erectile Dysfunction 1Epilepsy 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Anastrozole × Endocrine × Clear all
NCT00179517 2019-07-17

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

Beth Israel Deaconess Medical Center

Phase 2 Completed
40 enrolled 13 charts
EndocrineOther

Epilepsy, Hypogonadism, Erectile Dysfunction, Seizures, Sexual Dysfunction, Physiological, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡